Pragmatic study of orlistat 60 mg on abdominal obesity

Thomas, E. Louise; Newbould, Rexford D.; Rao, Anil; Gambarota, Giulio; Frost, Gary; Delafont, Bruno; Mishra, Rajesh G.; Matthews, Paul M.; Berk, Evan S.; Schwartz, Susan M.; Bell, Jimmy D.; Beaver, John D.

doi:10.1038/ejcn.2011.108

Cited by 12 publications

(6 citation statements)

References 32 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, an open label, 3 month study using orlistat 60 mg was conducted to examine changes in fat distribution. The authors reported decreases in VAT and body weight at 12 weeks which were similar to the current results (14). Using proton magnetic resonance spectroscopy ( 1 H‐MRS), a 43% reduction in intra‐hepatocellular lipids was observed; in the current study, there was a 27% reduction in liver fat, based on CT. Hepatic measurements obtained by CT and liver biopsy correlate well with intra‐hepatocellular lipids as measured by 1 H‐MRS (30,31).…”

Section: Discussionsupporting

confidence: 91%

“…The 60 mg dose has been shown to have approx 85% the efficacy of the 120 mg dose (11,12). Some preliminary studies have examined the effect of orlistat 120 mg capsules on changes in body composition (13,14,15). In particular, Tiikkainen et al (13) showed that the 120 mg dose of orlistat was effective in reducing visceral fat greater than diet alone, despite similar weight loss.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Orlistat 60 mg Reduces Visceral Adipose Tissue: A 24‐Week Randomized, Placebo‐Controlled, Multicenter Trial

Smith

Stenlöf

Greenway

et al. 2011

Obesity

View full text Add to dashboard Cite

It is well established that abdominal obesity or upper body fat distribution is associated with increased risk of metabolic and cardiovascular disease. The purpose of the present study was to determine if a 24 week weight loss program with orlistat 60 mg in overweight subjects would produce a greater change in visceral adipose tissue (VAT) as measured by computed tomography (CT) scan, compared to placebo. The effects of orlistat 60 mg on changes in total fat mass (EchoMRI‐AH and BIA), ectopic fat (CT) and glycemic variables were assessed. One‐hundred thirty‐one subjects were randomized into a multicenter, double‐blind placebo controlled study in which 123 subjects received at least one post baseline efficacy measurement (intent‐to‐treat population). Both orlistat‐and placebo‐treated subjects significantly decreased their VAT at 24 weeks with a significantly greater loss of VAT by orlistat treated subjects (−15.7% vs. −9.4%, P < 0.05). In addition, orlistat‐treated subjects had significantly greater weight loss (−5.93 kg vs. −3.94 kg, P < 0.05), total fat mass loss (−4.65 kg vs. −3.01 kg, P < 0.05) and trended to a greater loss of intermuscular adipose tissue and content of liver fat compared with placebo‐treated subjects. This is the first study to demonstrate that orlistat 60 mg significantly reduces VAT in addition to total body fat compared to placebo treated subjects after a 24 week weight loss program. These results suggest that orlistat 60 mg may be an effective weight loss tool to reduce metabolic risk factors associated with abdominal obesity.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Orlistat 60 mg Reduces Visceral Adipose Tissue: A 24‐Week Randomized, Placebo‐Controlled, Multicenter Trial

Smith

Stenlöf

Greenway

et al. 2011

Obesity

View full text Add to dashboard Cite

show abstract

“…51,55 The remaining 12 studies (2 studies were single-group pre-post designs, 1 study had a more active comparison group, and 9 studies reported outcomes at < 12 mo) were only included in analyses of adverse events. 24,29,57,63,[75][76][77][78][79][80][81]83 High within-group heterogeneity was common; however, the direction of treatment effect was consistent across most studies, and the confidence intervals overlapped. This statistical heterogeneity is likely due to small versus large treatment effects observed across studies.…”

Section: Resultsmentioning

confidence: 99%

Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis

et al. 2014

View full text Add to dashboard Cite

“…Improvements in blood pressure, waist circumference, total cholesterol and LDL cholesterol were also greater with orlistat than with placebo . Even at the over‐the‐counter dose of 60 mg three times daily (brand name Alli®), improvements in body composition, lipid profiles and blood pressure may be observed . Orlistat has well‐known gastrointestinal adverse events, including faecal leakage .…”

Section: Current Status Of Pharmacological Weight Management In the Umentioning

confidence: 99%

Current and emerging medications for overweight or obesity in people with comorbidities

Fujioka

2015

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

Recently, the recognition of obesity as a complex disease that requires chronic management has become more widespread. There has also been a movement away from a focus on body mass index alone, and toward the management of obesity‐related comorbidities as well as excess weight. This article examines the current and emerging pharmacological options for weight management in people with overweight or obesity who have, or are at a high risk of, weight‐related comorbidities. In the USA, the current options for pharmacological weight management are phentermine (indicated for short‐term use only), orlistat, combined phentermine/topiramate extended release, lorcaserin, naltrexone/bupropion and liraglutide 3.0 mg. Currently, orlistat, naltrexone/bupropion and liraglutide 3.0 mg are approved in Europe. All of the above‐mentioned medications have shown weight‐loss efficacy versus placebo. Those approved for long‐term weight management have also been associated with improvements in weight‐related comorbidities, such as hypertension, prediabetes, diabetes or dyslipidaemia, or related biomarkers. As with all drugs, the safety and tolerability profiles of medications for weight management should be considered alongside their efficacy to ensure correct use. Additional medications for weight management that are in clinical development include bupropion/zonisamide and beloranib. The field of obesity treatment is advancing with a number of medications being recently approved, and with other pharmacological options emerging.

show abstract

Pragmatic study of orlistat 60 mg on abdominal obesity

Abstract: Background and Aims: It is well established combining a reduced calorie, low fat diet with

Cited by 12 publications

References 32 publications

Orlistat 60 mg Reduces Visceral Adipose Tissue: A 24‐Week Randomized, Placebo‐Controlled, Multicenter Trial

Orlistat 60 mg Reduces Visceral Adipose Tissue: A 24‐Week Randomized, Placebo‐Controlled, Multicenter Trial

Treatment for overweight and obesity in adult populations: a systematic review and meta-analysis

Current and emerging medications for overweight or obesity in people with comorbidities

Contact Info

Product

Resources

About